Table 3.

Markers of angiogenesis

		Intermittent HBO		Daily HBO
		Tumor	Stroma	Tumor	Stroma
Genes	Gene name	Fold change	Fold change	Fold change	Fold change
Anti-Angiogenic
Serpinb5	Serine (or cysteine) peptidase inhibitor, clade B, member 5	3.4	1.6	5.0	NS
Csta	Cystatin A	0.1	NS	NS	NS
Thbs1	Thrombospondin1	0.5	0.5	NS	NS
Thbs2	Thrombospondin2	NS	2.7	NS	2.5
Thbs3	Thrombospondin3	NS	NS	0.7	NS
Thbs4	Thrombospondin4	0.8	NS	NS	NS
Pro-angiogenic
HIF1a	Hypoxia-inducible factor 1, alpha	NS	NS	0.7	NS
Pecam1	Platlet/endothelial cell adhesion molecule 1	0.9	0.5	0.6	NS
Vwf	Von Willebrand factor homolog	0.7	0.3	NS	0.6
Vegfa	Vascular endothelial growth factor A	0.5	0.5	NS	1.4
Vegfb	Vascular endothelial growth factor B	NS	NS	0.7	NS
Vegfc	Vascular endothelial growth factor C	0.6	NS	0.5	NS
Pdgfa	Platelet derived growth factor, alpha	0.8	0.7	NS	NS
Pdgfb	Platelet derived growth factor, b	1.2	0.7	NS	NS
Pdgfra	Platelet derived growth factor receptor, alpha	0.7	2.3	0.5	2.1
Tgfb1	Transforming growth factor, beta 1	NS	0.8	0.8	NS
Il6	Interleukin 6	0.5	NS	NS	0.3
Fgfr1	Fibroblast growth factor receptor 1	0.9	NS	NS	NS
Fgfr3	Fibroblast growth factor receptor 3	0.7	NS	0.7	NS
Egfr	Epidermal growth factor receptor	0.5	NS	0.5	2.7
Serpinb2	Serine (or cysteine) peptidase inhibitor, clade B, member 2	0.6	NS	NS	0.5

Displayed results are fold change of gene expression in intermittent and daily hyperbaric oxygen (HBO) treated tumors cells compared to untreated control tumor cells, and intermittent and daily HBO treated stromal cells compared to untreated stromal cells. A positive fold change indicates increased expression after treatment. FDR < 0.05%, NS = not significant